KR102249982B1 - 트랜스포존 시스템, 이를 포함한 키트, 및 이들의 용도 - Google Patents

트랜스포존 시스템, 이를 포함한 키트, 및 이들의 용도 Download PDF

Info

Publication number
KR102249982B1
KR102249982B1 KR1020187017078A KR20187017078A KR102249982B1 KR 102249982 B1 KR102249982 B1 KR 102249982B1 KR 1020187017078 A KR1020187017078 A KR 1020187017078A KR 20187017078 A KR20187017078 A KR 20187017078A KR 102249982 B1 KR102249982 B1 KR 102249982B1
Authority
KR
South Korea
Prior art keywords
promoter
vector
cells
cell
exogenous dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187017078A
Other languages
English (en)
Korean (ko)
Other versions
KR20180092989A (ko
Inventor
사레이나 치웅-위안 우
Original Assignee
게놈프론티어 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게놈프론티어 테라퓨틱스 인코포레이티드 filed Critical 게놈프론티어 테라퓨틱스 인코포레이티드
Publication of KR20180092989A publication Critical patent/KR20180092989A/ko
Application granted granted Critical
Publication of KR102249982B1 publication Critical patent/KR102249982B1/ko
Assigned to 게놈프론티어 테라퓨틱스 티더블유 컴퍼니 리미티드 reassignment 게놈프론티어 테라퓨틱스 티더블유 컴퍼니 리미티드 권리의 전부이전등록 Assignors: 게놈프론티어 테라퓨틱스 인코포레이티드
Assigned to 게놈프론티어 테라퓨틱스 코퍼레이션 reassignment 게놈프론티어 테라퓨틱스 코퍼레이션 권리의 전부이전등록 Assignors: 게놈프론티어 테라퓨틱스 티더블유 컴퍼니 리미티드
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020187017078A 2015-12-14 2016-12-12 트랜스포존 시스템, 이를 포함한 키트, 및 이들의 용도 Active KR102249982B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267270P 2015-12-14 2015-12-14
US62/267,270 2015-12-14
PCT/CN2016/109510 WO2017101749A1 (en) 2015-12-14 2016-12-12 Transposon system, kit comprising the same, and uses thereof

Publications (2)

Publication Number Publication Date
KR20180092989A KR20180092989A (ko) 2018-08-20
KR102249982B1 true KR102249982B1 (ko) 2021-05-11

Family

ID=59055731

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187017078A Active KR102249982B1 (ko) 2015-12-14 2016-12-12 트랜스포존 시스템, 이를 포함한 키트, 및 이들의 용도

Country Status (11)

Country Link
US (1) US11345926B2 (cg-RX-API-DMAC7.html)
JP (1) JP6956416B2 (cg-RX-API-DMAC7.html)
KR (1) KR102249982B1 (cg-RX-API-DMAC7.html)
CN (1) CN108474005B (cg-RX-API-DMAC7.html)
AU (1) AU2016373365B2 (cg-RX-API-DMAC7.html)
CA (1) CA3004665C (cg-RX-API-DMAC7.html)
MX (1) MX380289B (cg-RX-API-DMAC7.html)
MY (1) MY184126A (cg-RX-API-DMAC7.html)
NZ (1) NZ742068A (cg-RX-API-DMAC7.html)
TW (1) TWI609960B (cg-RX-API-DMAC7.html)
WO (1) WO2017101749A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
CA3047313A1 (en) 2016-12-16 2018-06-21 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
WO2019246486A2 (en) 2018-06-21 2019-12-26 B-Mogen Biotechnologies, Inc. ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
HUE068630T2 (hu) 2018-12-10 2025-01-28 Amgen Inc Mutáns PiggyBac transzpozáz
EP3898993A1 (en) * 2018-12-20 2021-10-27 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
KR102990253B1 (ko) * 2019-06-11 2026-07-10 우니베르시타트 폼페우 파브라 표적화된 유전자 편집 작제물 및 이의 사용 방법
WO2023282730A1 (ko) * 2021-07-09 2023-01-12 주식회사 네오젠티씨 트랜스포존 시스템 및 이의 용도
US20260234570A1 (en) * 2021-10-15 2026-08-13 Shenzhen Eureka Biotechnology Co., Limited Multi-transposon system

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157386A1 (en) 2014-04-10 2015-10-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Production of engineered t-cells by sleeping beauty transposon coupled with methotrexate selection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962810B2 (en) * 2000-10-31 2005-11-08 University Of Notre Dame Du Lac Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac
MX2007014139A (es) * 2005-05-14 2008-10-09 Univ Fudan Piggybac como una herramienta para manipulacion genetica y analisis en vertebrados.
US20090042297A1 (en) * 2007-06-01 2009-02-12 George Jr Alfred L Piggybac transposon-based vectors and methods of nucleic acid integration
KR20080041146A (ko) * 2007-12-13 2008-05-09 푸단 유니버시티 척추동물에서의 유전자 조작 및 분석을 위한 도구로서의피기백
US20110311506A1 (en) 2009-02-25 2011-12-22 The Johns Hopkins University Piggybac transposon variants and methods of use
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
EP3513802B1 (en) * 2012-10-26 2023-11-29 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
CN102943092B (zh) * 2012-11-20 2014-12-10 西北农林科技大学 一种通用型PiggyBac转座子转基因载体及其制备方法
EP2922959A4 (en) * 2012-11-20 2016-04-20 Simplot Co J R TAL-MEDIATED TRANSFER DNA INTRODUCTION
CN104342453A (zh) * 2013-08-06 2015-02-11 深圳先进技术研究院 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
WO2015139093A1 (en) 2014-03-21 2015-09-24 The Sydney Children's Hospitals Network (Randwick And Westmead) (Incorporating The Royal Alexandra Hospital For Children) Stable gene transfer to proliferating cells
HUE052552T2 (hu) * 2014-04-09 2021-05-28 Dna Twopointo Inc Javított nukleinsav-konstrukciók eukarióta génexpresszióhoz

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157386A1 (en) 2014-04-10 2015-10-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Production of engineered t-cells by sleeping beauty transposon coupled with methotrexate selection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BMC Biotechnology.,11:28(biomedcentral.com/1472-6750/11/28)(2011.3.30.)*
FASEB J.,27(11):4429-4443(2013.7.29.)
J Immunother.,32(8):826-836(2009.10.)

Also Published As

Publication number Publication date
TWI609960B (zh) 2018-01-01
AU2016373365B2 (en) 2021-07-08
JP6956416B2 (ja) 2021-11-02
US20180320196A1 (en) 2018-11-08
AU2016373365A1 (en) 2018-05-17
MX2018007203A (es) 2018-11-12
CA3004665C (en) 2021-08-24
CA3004665A1 (en) 2017-06-22
US11345926B2 (en) 2022-05-31
NZ742068A (en) 2023-07-28
MX380289B (es) 2025-03-12
JP2019503653A (ja) 2019-02-14
KR20180092989A (ko) 2018-08-20
WO2017101749A1 (en) 2017-06-22
CN108474005B (zh) 2022-10-21
MY184126A (en) 2021-03-19
CN108474005A (zh) 2018-08-31
TW201720926A (zh) 2017-06-16

Similar Documents

Publication Publication Date Title
JP7399866B2 (ja) CARTyrin組成物とその利用方法
AU2016373365B2 (en) Transposon system, kit comprising the same, and uses thereof
JP6684782B2 (ja) キメラ抗原受容体
KR20230029603A (ko) 필수 유전자 녹-인에 의한 선택
WO2020092057A1 (en) Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
KR20210091160A (ko) 면역요법을 위한 조성물 및 방법
JP2021507703A (ja) Vcar組成物とその利用法
AU2018264636B2 (en) Artificially manipulated immune cell
KR20220038362A (ko) 재조합 ad35 벡터 및 관련 유전자 요법 개선
KR20190130608A (ko) 면역종양학을 위한 조성물 및 방법
CN111909966B (zh) 一种制备经修饰的免疫细胞的方法
EP3359676B1 (en) Transposon system, kit comprising the same, and uses thereof
EP2914721B1 (en) A rna trans-splicing molecule (rtm) for use in the treatment of cancer
KR20210105947A (ko) 나노트랜스포존 조성물 및 사용 방법
KR20230002681A (ko) 대형 아데노바이러스 페이로드의 통합
WO2023138617A1 (zh) 工程化的CasX核酸酶、效应蛋白及其用途
KR20220057596A (ko) 동종이계 세포 조성물 및 사용 방법
US20250228940A1 (en) Compositions and methods for efficient and stable genetic modification of eukaryotic cells
CN117836420A (zh) 重组tert编码病毒基因组和运载体
RU2792187C2 (ru) Композиции cart-иринов и способы их применения
WO2025156492A1 (zh) 转座酶及其用途
WO2026003069A1 (en) Constructs and vectors for reprogramming cells to cdc1 cells, compositions and methods thereof
CN115803438A (zh) 用于cd3+细胞体外和体内表达基因治疗产物的启动子序列

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R14-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000